Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

(2013) T. Ueda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities

(2012) Roger B. Cohen et al.   INVESTIGATIONAL NEW DRUGS

Novel Agents and Approaches for Advanced Renal Cell Carcinoma

(2012) Robert Figlin et al.   JOURNAL OF UROLOGY

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

(2011) Yoshihiko Tomita et al.   EUROPEAN JOURNAL OF CANCER

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

(2009) Hassane Izzedine et al.   EUROPEAN JOURNAL OF CANCER

Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

(2009) Ronan J. Kelly et al.   Targeted Oncology

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib

(2008) T. V. Patel et al.   JNCI-Journal of the National Cancer Institute